newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras

Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose ("SAD") trial, commencing in Q2 2022, to compare fezag